Home›Companies›Preply

Preply, Inc.

Updated Oct 29, 2026·Latest SEC filing Jan 20, 2026·Suggest an edit

About Preply

Preply is a private company based in Brookline, Massachusetts. It has reported $212,660,470 raised in five offerings on Form D since November 2017.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Dec 31, 2025Jan 20, 2026$101,498,573of $120.9M target25$4.0MEquityRule 506(b)Form D ↗
Jun 17, 2023Jun 30, 2023$22,499,999of $32.5M target2$11.2MEquityRule 506(b)Form D ↗
Mar 16, 2022Mar 30, 2022$49,450,983of $79.7M target11$4.4MEquityRule 506(b)Form D ↗
Mar 2, 2021Mar 16, 2021$35,210,915of $35.9M target22$1.6MEquityRule 506(b)Form D ↗
Oct 19, 2017Nov 1, 2017$4,000,000fully sold16$250KEquityRule 506(b)Form D ↗
Total, five offerings$212,660,470

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Preply's Form D filed Jan 20, 2026.

AM
Allen Mask
Director
DV
Dmytro Voloshyn
Director
Also a director at Aviceda Therapeutics.
CW
Charlie Wickers
Chief Financial Officer
DB
MG
Mariusz Gralewski
Director
Also a director at Aviceda Therapeutics.
KB
Kyrylo Bigay
Executive officer and director
Also a president and director at Aviceda Therapeutics.

Earlier filings also listed Victor Patterson (director, last listed Jun 2023), Robert Kniaz (director, last listed Jun 2023), Ross Darwin (director, last listed Mar 2022) and Boris Shakhnovich (executive officer, last listed Nov 2017).

Sources

  1. SECPreply, Inc. filing history